Thromb Haemost 1982; 47(02): 173-176
DOI: 10.1055/s-0038-1657156
Original Article
Schattauer GmbH Stuttgart

A Thiazole Compound with Potential Antithrombotic Activity

E E Nishizawa
The Diabetes and Atherosclerosis Research Unit, The Upjohn Company, Kalamazoo, MI, U.S.A.
,
A R Mendoza
The Diabetes and Atherosclerosis Research Unit, The Upjohn Company, Kalamazoo, MI, U.S.A.
,
T Honohan
The Diabetes and Atherosclerosis Research Unit, The Upjohn Company, Kalamazoo, MI, U.S.A.
,
K A Annis
The Diabetes and Atherosclerosis Research Unit, The Upjohn Company, Kalamazoo, MI, U.S.A.
› Author Affiliations
Further Information

Publication History

Received 20 October 1981

Accepted 03 March 1982

Publication Date:
13 July 2018 (online)

Summary

A thiazole derivative, 4,5-bis(p-methoxyphenyl)-2-(trifluoromethyl)-thiazole was found to be a potent inhibitor of collagen-induced platelet aggregation, in vitro, using platelets from at least six species, including man. It was active in human platelet-rich plasma at a concentration of 1 ng/ml. While its antiplatelet activity was greater than that of flurbiprofen, its cyclooxygenase activity was equivalent to that of flurbiprofen. Also, compared to flurbiprofen, the thiazole had less anti-inflammatory activity in the hind-paw edema test. The thiazole derivative inhibited platelet aggregation following oral administration in five laboratory species. In the guinea pig it was active at 0.5 mg/kg. The LD50 in mice was greater than 1000 mg/kg (i.p.). This compound, which was designed through a systematic drug development program, may have high potential as an antithrombotic agent.

 
  • References

  • 1 Weiss HJ, Aledort LM, Kochwa S. The effect of salicylates on the hemostatic properties and platelets in man. J Clin Invest 1968; 47: 2169-2180
  • 2 Nishizawa EE, Wynalda DJ, Suydam DE, Molony BA. Flurbiprofen, a new potent inhibitor of platelet aggregation. Thromb Res 1973; 3: 577-588
  • 3 Cucuianu MP, Nishizawa EE, Mustard JF. Effect of pyrimido-pyrimidine compounds on platelet function. J Lab Clin Med 1971; 77: 958-974
  • 4 Nishizawa EE, Wynalda DJ. Inhibitory effect of ibuprofen (Motrin®) on platelet function. Thromb Res 1981; 21: 347-356
  • 5 McIntyre BA, Philp RB. Effect of three nonsteroidal anti-inflammatory agents on platelet function and prostaglandin synthesis in vitro. Thromb Res 1977; 12: 67-77
  • 6 Nishizawa EE, Wynalda DJ, Suydam DE, Sawa TR, Schultz JR. Collagen-induced pulmonary thromboembolism in mice. Thromb Res 1972; 1: 233-241
  • 7 Rynbrandt RH, Nishizawa EE, Balgoyen DP, Mendoza AR, Annis KA. Synthesis and platelet aggregation inhibitory activity of 4.5-Bis(aryl)-2-(substituted) thiazoles. J Med Chem 1981; 24: 1507-1510
  • 8 Costa JL, Murphy DL. Platelet 5-HT uptake and release stopped rapidly by formaldehyde. Nature 1975; 255: 407-408
  • 9 Glenn EM, Rohloff N, Bowman BJ, Lyster SC. The pharmacology of 2-(2-fluoro-4-Biphenyl) propionic acid (Flurbiprofen). A potent non-steroidal anti-inflammatory drug. Agents Actions 1973; 3/4: 210-216
  • 10 VanArman GC, Nuss GW, Risley EA. Interactions of aspirin, indomethacin, and other drugs in adjuvant induced arthritis in the rat. J Pharmacol Exp Ther 1973; 187: 400-413
  • 11 Winter CA, Risely EA, Nuss GW. Carrageenin induced edema in hind-paw of the rat as an assay for anti-inflammatory drugs. Proc Exp Biol Med 1962; III: 544-547
  • 12 Wallach DP, Brown VR. As novel preparation of human platelet lipoxygenase. Characteristics and inhibition by a variety of phenyl hydragoses and comparison with the lipoxygenases. Biochim Biophys Acta 1981; 632: 361-372